AtriCure, Inc. (ATRC)

AtriCure, Inc. (ATRC) Healthcare & Pipeline Overview

AtriCure, Inc. develops and markets surgical ablation devices for cardiac tissue, addressing atrial fibrillation and related conditions globally. With a 75.5% gross margin, the company focuses on innovative solutions like the Isolator Synergy Clamps and LARIAT System, serving medical centers through direct sales and distributors.

What Is the Investment Thesis for ATRC?

AtriCure, Inc. presents a compelling investment thesis centered on its innovative product portfolio and strategic positioning in the cardiac ablation market. The company's focus on surgical solutions for atrial fibrillation and related conditions addresses a significant and growing market need. Key value drivers include continued adoption of its advanced ablation technologies, such as the EPi-Sense and LARIAT systems, and expansion into new geographic markets. The company's high gross margin of 75.5% indicates strong pricing power and efficient operations. Upcoming catalysts include potential regulatory approvals for new products and expansion of clinical applications for existing devices. However, investors should be aware of potential risks, including competition from established medical device companies and the negative profit margin of -0.8%.

Based on FMP financials and quantitative analysis

ATRC Key Highlights

• Market capitalization of $1.66B reflects investor confidence in AtriCure's growth potential in the medical device market.
• Gross margin of 75.5% demonstrates strong pricing power and efficient cost management in the production and sale of surgical ablation devices.
• The company's focus on surgical ablation of cardiac tissue addresses a significant and growing market need, particularly in the treatment of atrial fibrillation.
• AtriCure's international presence, with sales in the United States, Europe, and Asia, provides diversification and growth opportunities.
• The company's portfolio of innovative products, including the Isolator Synergy Clamps and LARIAT System, positions it as a leader in the surgical ablation market.

Who Are ATRC's Competitors?

ATRC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATRC's Key Strengths?

• Innovative product portfolio in cardiac ablation.
• High gross margin of 75.5%.
• Established presence in key markets (US, Europe, Asia).
• Strong relationships with cardiac surgeons.

What Are ATRC's Weaknesses?

• Negative profit margin of -0.8%.
• Reliance on a limited number of key products.
• Exposure to regulatory risks and compliance requirements.
• Competition from larger medical device companies.

What Could Drive ATRC Stock Higher?

• Potential regulatory approvals for new ablation devices in key markets.
• Continued adoption of the LARIAT System in soft-tissue closure applications.
• Expansion of clinical applications for the EPi-Sense Guided Coagulation System.
• Strategic partnerships with leading medical centers and research institutions.

What Are the Key Risks for ATRC?

• Negative return on equity (-1.0%) — the business is not currently generating profit on shareholder capital.
• Rich valuation — a P/E of 92.9 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $4.8M recently.
• Intense competition from established medical device companies.
• Pricing pressures from hospitals and healthcare providers.
• Product liability claims and recalls.
• Changes in healthcare regulations and reimbursement policies.
• Negative profit margin impacting financial performance.

What Are the Growth Opportunities for ATRC?

• Expansion of the LARIAT System: The LARIAT System, a suture-based solution for soft-tissue closure, presents a significant growth opportunity for AtriCure. With increasing adoption in various anatomical applications, the LARIAT System can drive revenue growth. The market for soft-tissue closure devices is estimated to reach several billion dollars, offering substantial potential for AtriCure to expand its market share. The timeline for further adoption depends on clinical data and surgeon training, but ongoing efforts to promote the LARIAT System should yield results within the next 2-3 years.
• Increased Adoption of EPi-Sense Technology: The EPi-Sense Guided Coagulation System offers a growth avenue for AtriCure. As a single-use disposable device used for treating symptomatic, drug-refractory, and long-standing persistent atrial fibrillation, its increasing adoption can significantly impact revenue. The atrial fibrillation market is expanding due to aging populations and lifestyle factors, creating a larger patient pool. Wider adoption hinges on clinical outcomes and physician acceptance, with potential for significant growth within the next 3-5 years.
• Geographic Expansion into Emerging Markets: AtriCure has the opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions have a growing demand for advanced medical technologies and a rising prevalence of cardiac diseases. Entering these markets requires strategic partnerships and regulatory approvals, but the potential for revenue growth is substantial. The timeline for significant market penetration is 3-5 years, contingent on successful market entry strategies.
• Development of Next-Generation Ablation Technologies: Investing in research and development to create next-generation ablation technologies is crucial for AtriCure's long-term growth. This includes exploring new energy sources, improving device designs, and expanding the range of treatable cardiac conditions. The market for advanced ablation technologies is continuously evolving, and innovation is essential to maintain a competitive edge. The timeline for bringing new technologies to market is typically 3-5 years, requiring sustained investment and clinical trials.
• Strategic Acquisitions and Partnerships: AtriCure can pursue strategic acquisitions and partnerships to expand its product portfolio and market reach. This includes acquiring companies with complementary technologies or establishing partnerships with leading medical centers and research institutions. Strategic alliances can accelerate innovation and market access, creating synergies and driving revenue growth. The timeline for realizing the benefits of acquisitions and partnerships varies, but proactive deal-making can yield significant results within 2-3 years.

What Opportunities Does ATRC Have?

• Expansion into emerging markets.
• Development of next-generation ablation technologies.
• Strategic acquisitions and partnerships.
• Increased adoption of minimally invasive surgical techniques.

What Threats Does ATRC Face?

• Intense competition in the medical device industry.
• Pricing pressures from hospitals and healthcare providers.
• Product liability claims and recalls.
• Changes in healthcare regulations and reimbursement policies.

What Are ATRC's Competitive Advantages?

• Proprietary technology in surgical ablation.
• Established relationships with cardiac surgeons.
• Strong brand reputation in the cardiac surgery market.
• Portfolio of single-use disposable products generating recurring revenue.

What Does ATRC Do?

AtriCure, Inc., founded in 2000 and headquartered in Mason, Ohio, is a medical device company focused on developing, manufacturing, and selling innovative surgical ablation solutions. The company's core business revolves around devices used for the surgical ablation of cardiac tissue and systems, as well as intercostal nerves. These products are distributed to medical centers in the United States, Europe, Asia, and other international markets. AtriCure offers a range of products, including the Isolator Synergy Clamps, multifunctional pens like the MAX Pen device, and the Coolrail device, each designed to address specific needs in cardiac ablation procedures. The MAX Pen, for example, allows surgeons to evaluate cardiac arrhythmias, perform temporary pacing, and ablate tissue using a single device. The company also provides the cryoICE Cryoablation System for linear ablations, the EPi-Sense Guided Coagulation System for atrial fibrillation treatment, the AtriClip System, and the LARIAT System for soft-tissue closure. Furthermore, AtriCure offers ancillary products such as Lumitip Dissectors, Glidepath guides, and Subtle Cannula's, enhancing the overall surgical experience. These products are marketed and sold through a combination of independent distributors and a direct sales force, ensuring broad market access and customer support.

What Products and Services Does ATRC Offer?

• Develops surgical ablation devices for cardiac tissue.
• Manufactures devices for treating atrial fibrillation.
• Sells products to medical centers in the United States, Europe, and Asia.
• Offers the Isolator Synergy Clamps for radio frequency ablation.
• Provides the MAX Pen device for cardiac arrhythmia evaluation and ablation.
• Markets the LARIAT System for soft-tissue closure.
• Offers cryoICE Cryoablation System for linear ablations.

How Does ATRC Make Money?

• Develops and manufactures surgical ablation devices.
• Sells devices to hospitals and medical centers.
• Utilizes a direct sales force and independent distributors.
• Generates revenue through the sale of disposable and reusable devices.

What Industry Does ATRC Operate In?

AtriCure operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and demand for advanced medical technologies. The market for cardiac ablation devices is driven by the increasing prevalence of atrial fibrillation and other cardiac arrhythmias. Competition includes established medical device companies and emerging players offering alternative ablation technologies. AtriCure's focus on surgical ablation solutions differentiates it within the broader market, positioning it to capitalize on the demand for effective and minimally invasive treatments. This industry is subject to stringent regulatory requirements and technological advancements.

Who Are ATRC's Key Customers?

• Hospitals and medical centers.
• Cardiac surgeons.
• Electrophysiologists.
• Patients with atrial fibrillation and other cardiac arrhythmias.

Net buyingInsider Activity

Over the past six months, AtriCure, Inc. insiders filed 30 SEC Form 4 transactions — 11 sales and 19 purchases. On net that is roughly 257K shares acquired (about $4.8M) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project AtriCure, Inc. revenue of about $605.2M for fiscal 2026, with EPS near $0.04. The estimate reflects 7 contributing analysts.

F-Score 6/9Financial Health

AtriCure, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.77 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -1%Key Financial Metrics

Return on equity for AtriCure, Inc. stands at -1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.3%, the inverse of the P/E and a quick read on earnings relative to price.

AtriCure, Inc. (ATRC) Valuation Context

Valued at $1.66B, ATRC is classified as a small-cap stock. Relative to its peer group, ATRC's quantitative score of 39/100 is below the peer average of 76/100.

ATRC Revenue & Earnings Trend

In Q1 2026, ATRC generated $141.2M in top-line revenue, marking a sequential increase of 0.5%. The company recorded net income of $108K, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, ATRC averaged $-0.02 in diluted EPS.

Company Profile

AtriCure, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Mason, US. The company is led by CEO Michael H. Carrel. ATRC has traded publicly since 2005.

ATRC Financials

ATRC Latest News

ATRC Analyst Consensus

ATRC MoonshotScore

Latest AtriCure, Inc. Analysis

ATRC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources